Regenerative medicine and stem cells partnering terms and agreements


Published on

Published in: Business
  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Regenerative medicine and stem cells partnering terms and agreements

  1. 1. Regenerative Medicine and Stem Cells Partnering Terms and AgreementsDescription The Regenerative Medicine and Stem Cells Partnering Terms and Agreements report provides comprehensiveunderstanding and unprecedented access to the Regenerative medicine and Stem cells partnering deals andagreements entered into by the worlds leading healthcare companies. Trends in regenerative medicine and stem cells deals Deal terms analysis Partnering agreement structurePartnering contract documents Top deals by value Most active dealmakers Average deal terms forregenerative medicine and stem cells The report provides a detailed understanding and analysis of how andwhy companies enter regenerative medicine and stem cells partnering deals. The majority of deals aredevelopment stage whereby the licensee obtains a right or an option right to license the licensors regenerativemedicine and stem cells technology. These deals tend to be multicomponent, starting with collaborative R&D,and commercialization of outcomes. This report provides details of the latest regenerative medicine and stem cells agreements including celltherapy agreements announced in the healthcare sector. Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insightinto the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilstmany smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms ofhow payments are triggered – contract documents provide this insight where press releases anddatabases do not. This report contains a comprehensive listing of all regenerative medicine and stem cells partnering dealsannounced since 2008 including financial terms where available including over 550 links to online dealrecords as disclosed by the deal parties. In addition, where available, records include contract documents assubmitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’sflexibility on a wide range of important issues, many of which will have a significant impact on eachparty’s ability to derive value from the deal. For example, analyzing actual company deals and agreements allows assessment of the following: What isactually granted by the agreement to the partner company? What exclusivity is granted? What are the preciserights granted or optioned? What is the payment structure for the deal? How aresalesand payments audited?What is the deal term? How are the key terms of the agreement defined? How are IPRs handled and owned?Who is responsible for commercialization? Who is responsible for development, supply, and manufacture?How is confidentiality and publication managed? How are disputes to be resolved? Under what conditions canthe deal be terminated? What happens when there is a change of ownership? What sublicensing andsubcontracting provisions have been agreed? Which boilerplate clauses does the company insist upon? Whichboilerplate clauses appear to differ from partner to partner or deal type to deal type? Which jurisdiction doesthe company insist upon for agreement law? The initial chapters of this report provide an orientation of drug dealmaking and business activities. Chapter 1provides an introduction to the report, whilst chapter 2 provides an overview of the trends in regenerativemedicine and stem cells dealmaking since 2009, including details of average headline, upfront, milestone androyalty terms.Regenerative Medicine and Stem Cells Partnering Terms and Agreements
  2. 2. Chapter 3 provides a review of the leading regenerative medicine and stem cells deals since 2009. Deals arelisted by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharmacompanies. Where the deal has an agreement contract published at the SEC a link provides online access to thecontract. Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summaryfollowed by a comprehensive listing of regenerative medicine and stem cells deals, as well as contractdocuments available in the public domain. Where available, each deal title links via Weblink to an onlineversion of the actual contract document, providing easy access to each contract document on demand. Chapter 5 provides a comprehensive and detailed review of regenerative medicine and stem cells partneringdeals signed and announced since 2009, where a contract document is available in the public domain. Thechapter is organized by stage of development at signing, deal type (collaborative R&D, co-promotion,licensing etc), specific therapy focus and specific technology type . Each deal title links via Weblink to anonline version of the deal record and where available, the contract document, providing easy access to eachcontract document on demand. The report also includes numerous tables and figures that illustrate the trends and activities in regenerativemedicine and stem cells partnering and dealmaking since 2009. In addition, a comprehensive appendix is provided organized by regenerative medicine and stem cellspartnering company A-Z , deal type definitions and regenerative medicine and stem cells partneringagreements example. Each deal title links via Weblink to an online version of the deal record and whereavailable, the contract document, providing easy access to each contract document on demand. In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in theresearch, development and commercialization of regenerative medicine and stem cells technologies andproducts. Benefits Regenerative Medicine and Stem Cells Partnering Terms and Agreements provides the reader with thefollowing key benefits: In-depth understanding of regenerative medicine and stem cells deal trends since 2007 Access to headline,upfront, milestone and royalty data Analysis of the structure of regenerative medicine and stem cellsagreements with numerous real life case studies Comprehensive access to over 1500 actual regenerativemedicine and stem cells contracts entered into by the world’s biopharma companies Detailed access toactual regenerative medicine and stem cells contracts enter into by the leading fifty bigpharma companiesInsight into the terms included in a regenerative medicine and stem cells agreement, together with real worldclause examples Understand the key deal terms companies have agreed in previous deals Undertake duediligence to assess suitability of your proposed deal terms for partner companiestableofcontentschapter1–introductionchapter2–trendsinregenerativemedicineandstemcellsdealmaking2.1.introductionRegenerative Medicine and Stem Cells Partnering Terms and Agreements
  3. 3. 2.2.regenerativemedicineandstemcellspartneringovertheyears2.3.bigpharmaregenerativemedicineandstemcellsdealmakingactivity2.4.regenerativemedicineandstemcellspartneringbydealtype2.5.regenerativemedicineandstemcellspartneringbydiseasetype2.6.partneringbyregenerativemedicineandstemcellstechnologytype2.7.averagedealtermsforregenerativemedicineandstemcellspartnering2.7.1regenerativemedicineandstemcellsheadlinevalues2.7.2regenerativemedicineandstemcellsupfrontpayments2.7.3regenerativemedicineandstemcellsmilestonepayments2.7.4regenerativemedicineandstemcellsroyaltyrates2.8.theanatomyofregenerativemedicineandstemcellspartnering2.9.theanatomyofaregenerativemedicineandstemcellsdeal2.9.a.casestudy1:oregonhealth&scienceuniversity-regenbiopharma-june20122.9.b.casestudy2:thermogenesis-nanshanmemorialmedicalinstitute-november20102.9.c.casestudy3:ascenttherapeutics-bioheart-january2010chapter3–leadingregenerativemedicineandstemcellsdeals3.1.introduction3.2.topregenerativemedicineandstemcellsdealsbyvaluechapter4–bigpharmaregenerativemedicineandstemcellsdeals4.1.introduction4.2.howtousebigpharmaregenerativemedicineandstemcellspartneringdeals4.3.bigpharmaregenerativemedicineandstemcellspartneringcompanyprofilesabbottastellasastrazenecabayerboehringeringelheimbristol-myerssquibbeisaielilillyglaxosmithklinejohnson&johnsonkyowahakkokirinmerck&conovartisotsukapfizerrochesanofiRegenerative Medicine and Stem Cells Partnering Terms and Agreements
  4. 4. tevaucbchapter5–regenerativemedicineandstemcellspartneringcontractsdirectory5.1.introduction5.2.companya-z5.3.bydealtypeassetpurchaseco-developmentcollaborativer&dcontractserviceco-promotiondevelopmentdistributionequitypurchaselicensingmanufacturingmarketingmaterialtransferoptionresearchsub-licensetechnologytransfertermination5.4.bystageofdevelopmentdiscoveryphaseipreclinical5.5.bytherapyareacardiovasculargeneticdisordershematologyhospitalcareimmunologymusculoskeletaloncologyophthalmicsrespiratorychapter6–regenerativemedicineandstemcellsdealmakingbytechnologytype6.1.introductionRegenerative Medicine and Stem Cells Partnering Terms and Agreements
  5. 5. 6.2.dealsbycelltherapy,regenerativemedicineandstemcellstypecelltherapyregenerativemedicinestemcellsappendicesintroductionappendix1–directoryofregenerativemedicineandstemcellsdealsbycompanya-z2009-2013appendix2–directoryofregenerativemedicineandstemcellsdealsbystageofdevelopment2009-2012discoveryformulationmarketedphaseiphaseiiphaseiiipreclinicalregulatoryappendix3–directoryofregenerativemedicineandstemcellsdealsbydealtype2009-2012assetpurchasebigpharmaoutlicensingco-developmentcollaborativer&dco-marketcontractserviceco-promotioncradacross-licensingdevelopmentdistributionequitypurchaseevaluationgrantinterestsjointventurelicensinglitigationmanufacturingmarketingmaterialtransferoptionpromotionresearchRegenerative Medicine and Stem Cells Partnering Terms and Agreements
  6. 6. royaltyfinancingsettlementspinoutsub-licensesupplytechnologytransferterminationwarrantyappendix4–directoryofregenerativemedicineandstemcellsdealsbytherapyarea2009-2012cardiovascularcentralnervoussystemdental768dermatologygastrointestinalgeneticdisordersgenitourinaryhematologyhospitalcareimmunologyinfectivesmetabolicmusculoskeletalobstetricsoncologyophthalmicspediatricsrespiratoryappendix5–regenerativemedicineandstemcellspartneringresourcecenteronlineregenerativemedicineandstemcellspartneringregenerativemedicineandstemcellspartneringeventsfurtherreadingonregenerativemedicineandstemcellsdealmakingaboutwildwoodventurescurrentpartneringcurrentagreementscurrentreportsrecenttitlesfromcurrentpartneringorderform–reportsAbout Us:Transparency Market Research is a market intelligence company providing global business informationreports and services. Our exclusive blend of quantitative forecasting and trends analysis providesforward-looking insight for thousands of decision makers. We are privileged with highly experienced team ofAnalysts, Researchers and Consultants, who use proprietary data sources and various tools and techniques toRegenerative Medicine and Stem Cells Partnering Terms and Agreements
  7. 7. gather, and analyze information. Our business offerings represent the latest and the most reliable informationindispensable for businesses to sustain a competitive edge.Contact:ResearchMoz90 State Street,Suite 700,Albany NY - 12207United StatesTel: +1-518-618-1030USA - Canada Toll Free 866-997-4948Email: sales@researchmoz.usBlog: Medicine and Stem Cells Partnering Terms and Agreements